These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20959470)

  • 21. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
    Blakey DC; Westwood FR; Walker M; Hughes GD; Davis PD; Ashton SE; Ryan AJ
    Clin Cancer Res; 2002 Jun; 8(6):1974-83. PubMed ID: 12060643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
    Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
    Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.
    Tsunetoh S; Terai Y; Sasaki H; Tanabe A; Tanaka Y; Sekijima T; Fujioka S; Kawaguchi H; Kanemura M; Yamashita Y; Ohmichi M
    Cancer Biol Ther; 2010 Dec; 10(11):1137-46. PubMed ID: 20935474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan.
    Rosanò L; Spinella F; Di Castro V; Natali PG; Bagnato A
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S132-5. PubMed ID: 15838262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo.
    Zhang XY; Chen J; Zheng YF; Gao XL; Kang Y; Liu JC; Cheng MJ; Sun H; Xu CJ
    Cancer Res; 2009 Aug; 69(16):6506-14. PubMed ID: 19638590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer.
    Hong SS; Zhang MX; Zhang M; Yu Y; Chen J; Zhang XY; Xu CJ
    Drug Deliv; 2018 Nov; 25(1):576-584. PubMed ID: 29461120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraperitoneal Delivery of Cisplatin via a Hyaluronan-Based Nanogel/in Situ Cross-Linkable Hydrogel Hybrid System for Peritoneal Dissemination of Gastric Cancer.
    Ohta S; Hiramoto S; Amano Y; Emoto S; Yamaguchi H; Ishigami H; Kitayama J; Ito T
    Mol Pharm; 2017 Sep; 14(9):3105-3113. PubMed ID: 28806513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor targeting using polyamidoamine dendrimer-cisplatin nanoparticles functionalized with diglycolamic acid and herceptin.
    Kesavan A; Ilaiyaraja P; Sofi Beaula W; Veena Kumari V; Sugin Lal J; Arunkumar C; Anjana G; Srinivas S; Ramesh A; Rayala SK; Ponraju D; Venkatraman G
    Eur J Pharm Biopharm; 2015 Oct; 96():255-63. PubMed ID: 26277659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted delivery of platinum-taxane combination therapy in ovarian cancer.
    Desale SS; Soni KS; Romanova S; Cohen SM; Bronich TK
    J Control Release; 2015 Dec; 220(Pt B):651-9. PubMed ID: 26381902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8.
    Huang S; Robinson JB; Deguzman A; Bucana CD; Fidler IJ
    Cancer Res; 2000 Oct; 60(19):5334-9. PubMed ID: 11034066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer.
    Wang Y; Liu P; Duan Y; Yin X; Wang Q; Liu X; Wang X; Zhou J; Wang W; Qiu L; Di W
    Biomaterials; 2014 Jan; 35(3):983-92. PubMed ID: 24176193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells.
    Wild R; Dhanabal M; Olson TA; Ramakrishnan S
    Br J Cancer; 2000 Oct; 83(8):1077-83. PubMed ID: 10993657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice.
    Zhong Q; Wen YJ; Yang HS; Luo H; Fu AF; Yang F; Chen LJ; Chen X; Qi XR; Lin HG; Wan Y; Chen XC; Wei YQ; Zhao X
    Ann Oncol; 2008 Sep; 19(9):1584-91. PubMed ID: 18436522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation.
    Shathasivam P; Kollara A; Spybey T; Park S; Clarke B; Ringuette MJ; Brown TJ
    Br J Cancer; 2017 Apr; 116(8):1065-1076. PubMed ID: 28301874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tie2-mediated vascular remodeling by ferritin-based protein C nanoparticles confers antitumor and anti-metastatic activities.
    Choi YS; Jang H; Gupta B; Jeong JH; Ge Y; Yong CS; Kim JO; Bae JS; Song IS; Kim IS; Lee YM
    J Hematol Oncol; 2020 Sep; 13(1):123. PubMed ID: 32928251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy.
    Manenti L; Riccardi E; Marchini S; Naumova E; Floriani I; Garofalo A; Dossi R; Marrazzo E; Ribatti D; Scanziani E; Bani M; Belotti D; Broggini M; Giavazzi R
    Mol Cancer Ther; 2005 May; 4(5):715-25. PubMed ID: 15897235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Folate-Targeted and Oxygen/Indocyanine Green-Loaded Lipid Nanoparticles for Dual-Mode Imaging and Photo-sonodynamic/Photothermal Therapy of Ovarian Cancer in Vitro and in Vivo.
    Liu Y; Chen S; Sun J; Zhu S; Chen C; Xie W; Zheng J; Zhu Y; Xiao L; Hao L; Wang Z; Chang S
    Mol Pharm; 2019 Oct; 16(10):4104-4120. PubMed ID: 31517495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
    Bratasz A; Selvendiran K; Wasowicz T; Bobko A; Khramtsov VV; Ignarro LJ; Kuppusamy P
    J Transl Med; 2008 Feb; 6():9. PubMed ID: 18302761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.